HealthMap

Corticosteroids and VLDL Triglyceride Levels

Overview of Effects

• Long-term or high-dose corticosteroid use (such as prednisone, cortisone, or dexamethasone) frequently causes significant disruptions in lipid metabolism.
• Elevated VLDL (Very Low-Density Lipoprotein) and triglyceride levels are a well-documented metabolic side effect of prolonged steroid therapy.

Mechanism of Elevation

• Increased Hepatic Production: Steroids stimulate the liver to synthesize and secrete higher amounts of VLDL particles, which are the primary carriers of endogenous triglycerides.
• Decreased Lipoprotein Lipase Activity: Corticosteroids can impair the function of lipoprotein lipase, the enzyme responsible for breaking down triglycerides in the bloodstream, leading to delayed clearance.
• Insulin Resistance: Steroids commonly induce a state of insulin resistance. Elevated insulin and glucose levels further signal the liver to produce more triglycerides and VLDL.

Clinical Implications

• Patients undergoing long-term steroid therapy often present with combined hyperlipidemia, characterized by elevated triglycerides, increased VLDL, and sometimes elevated LDL cholesterol.
• This lipid profile can increase long-term cardiovascular risks and contribute to metabolic syndrome-like symptoms.

Nutritional and Metabolic Considerations

• Dietary modifications focusing on the reduction of refined carbohydrates and sugars are essential, as excess carbohydrates synergize with steroids to worsen hypertriglyceridemia.
• Targeted nutritional support, such as adequate intake of omega-3 fatty acids (EPA/DHA), niacin, or specific antioxidants, is often utilized in clinical nutrition to help mitigate steroid-induced lipid imbalances.
• Monitoring baseline and follow-up lipid panels is critical for individuals requiring extended corticosteroid treatment.